Gary Meininger, MD, is Executive Vice President and Chief Medical Officer at Sana Biotechnology.

Prior to joining Sana, Gary served as Senior Vice President and Head of Clinical Development at Vertex Cell and Genetic Therapies (VCGT), where he oversaw all aspects of clinical development for VCGT disease areas, including sickle cell disease, beta-thalassemia, type 1 diabetes, and Duchenne muscular dystrophy.

Prior to Vertex, Gary spent more than eight years at Janssen where he served as Vice President, Franchise Medical Leader in the Cardiovascular-Metabolism Therapeutic Area. In this strategic role, Gary oversaw the design, development and conduct of study programs, as well as the associated regulatory interactions, filings and approvals for various products including Invokana® (canagliflozin) and Invokamet® (canagliflozin/metformin) for the treatment of glycemic control, cardiovascular disease, and diabetic nephropathy in patients with type 2 diabetes. Prior to joining Janssen, Gary worked at Merck Research Laboratories for eight years where he was a core member of the Januvia® (sitagliptin) and Janumet® (sitagliptin/metformin) development programs and oversaw several development programs from discovery through late development.

Gary is the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee. He has authored over 60 publications in metabolic, cardiovascular, and renal diseases. For over 16 years, Gary maintained an endocrine clinical practice at Robert Wood Johnson University Hospital where he taught medical students, residents and fellows and maintained a faculty appointment at Rutgers Medical School.

Gary completed his residency in Internal Medicine at New York-Presbyterian Hospital and his fellowship in Endocrinology at the Massachusetts General Hospital. He obtained a B.S. in Biological Sciences from Binghamton University and an MD from New York University School of Medicine.